How did CMND's expenses impact profits in Q1 2025?

Clearmind Medicine's (CMND) net income was negatively impacted by $1.07 million in costs of goods sold (COGS) in Q1 2025, resulting in a total net loss for the period. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |CMND|CMND.O|Clearmind Medicine|2024 Q2|56.25963815906707|-908217|186| |CMND|CMND.O|Clearmind Medicine|2024 Q3|-264.0410857686283|-2093917|186| |CMND|CMND.O|Clearmind Medicine|2024 Q4|78.2607445723978|-884744|186| |CMND|CMND.O|Clearmind Medicine|2025 Q1|21.653677438221962|-1071621|186| |code|Ticker|Name|Date|Net Income YoY|Cost of Goods Sold|market_code| |---|---|---|---|---|---|---| |CMND|CMND.O|Clearmind Medicine|2024 Q2|56.25963815906707||186| |CMND|CMND.O|Clearmind Medicine|2024 Q3|-264.0410857686283||186| |CMND|CMND.O|Clearmind Medicine|2024 Q4|78.2607445723978||186| |CMND|CMND.O|Clearmind Medicine|2025 Q1|21.653677438221962||186|